Establishment Labs Holdings Showcases Women's Health Innovations at Key November Conferences

Establishment Labs Expands Presence in Women's Health at Key Conferences

Establishment Labs Holdings Inc., a prominent player in the medical technology sector focused on enhancing women’s health, is set to make a significant impact at three major investment conferences in November 2024. This strategic participation underscores the company’s commitment to advancing breast aesthetics and reconstruction. CEO Juan José Chacón-Quirós and CFO Raj Denhoy will represent the company at the 2024 UBS Global Healthcare Conference, where they will present insights on the company’s innovative products and growth trajectory on November 12. This conference presents a critical platform for Establishment Labs to engage with industry stakeholders and showcase its leadership in developing cutting-edge solutions for women's health.

In addition to the UBS conference, Chacón-Quirós will speak at the 2024 Jefferies London Healthcare Conference on November 20, while Denhoy is scheduled to present at the 2024 Stephens Annual Investment Conference on November 21. These engagements not only highlight the company's innovative approaches but also its dedication to transparency and communication with investors and healthcare professionals. Live webcasts of the presentations will be available, allowing a broader audience to gain insights into Establishment Labs' advancements in medical technology, particularly its Motiva® devices and emerging solutions like Mia Femtech™.

Establishment Labs’ commitment to innovation is evident in its impressive portfolio, which includes nearly four million Motiva® devices distributed to over 85 countries. The company’s Motiva Flora® tissue expander stands out as the only regulatory-approved expander globally that integrates radio-frequency technology for MRI compatibility. This focus on patient safety and satisfaction aligns with the company's mission to redefine standards in breast reconstruction. With over 200 patent applications and more than 100 published studies, Establishment Labs exemplifies a strong commitment to research and development, further solidifying its position as a leader in the women's health sector.

In addition to its innovative products, Establishment Labs operates two state-of-the-art manufacturing facilities in Costa Rica, adhering to rigorous ISO13485:2016 and FDA regulations under the MDSAP program. This compliance ensures the highest standards of quality and safety in their manufacturing processes. The upcoming conferences provide an opportunity for Establishment Labs to reinforce its dedication to excellence and showcase the groundbreaking technologies that are shaping the future of breast aesthetics and reconstruction. For further details, interested parties can visit the company’s investor relations website.